Quintiles Confirms 'Go Public' Speculation with IPO and Predicts Rosy Future for CROs
Quintiles painted a rosy picture of the CRO sector in its much anticipated IPO, predicting that biopharma R&D spending will increase and demand for outsourced research will grow.